SAN FRANCISCO, January 12, 2016 /PRNewswire/ --
Our Analysis Reveals That Tongue and Buccal Cancers Harbor a set of Dual-purpose Tumor Neo-antigens That can be Used as Cancer Vaccines in a Therapeutic Setting, and as Biomarkers of Response to Select Patients for Cancer Immunotherapy
MedGenome will present results from their Head & Neck cancer study in which published genomics data from over 400 Head & Neck cancer samples have been analyzed to identify potential vaccine candidates using MedGenome's proprietary OncoPept platform at the Novel Immunotherapeutics Summit 2016, on January 25-26, 2016 at San Diego, CA .
The analysis shows that differential gene expression between tongue and buccal cancers produce both unique and shared vaccine candidates that can be used in combination therapies. Several studies have shown that the efficacy and durability of response to the checkpoint control inhibitors, which complement the traditional approach of targeting driver genes in cancer, are significantly enhanced by combining vaccine candidates derived from neo-antigens expressed by the tumor cells.
MedGenome's OncoPept is an integrated platform that uses exome sequencing, RNA sequencing and computational methods to characterize tumor neo-antigens, analyze T-cell neo-epitopes and reveal gene expression signatures. The platform has various pre-clinical and clinical research applications.
MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing (NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers.
For more information, visit us at http://www.medgenome.com
This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For more details, contact:
Director - Corporate Planning
MedGenome Labs Pvt. Ltd.
SOURCE MedGenome Labs Pvt. Ltd.